XML 22 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
Preferred Stock
Series Seed Preferred Stock
Preferred Stock
Series A preferred stock
Preferred Stock
Series B Preferred Stock
Preferred Stock
Series A Convertible Preferred Stock
Preferred Stock
Series C convertible preferred stock
Preferred Stock
Series A-2 Preferred Stock
Preferred Stock
Series A-3 Preferred Stock
Preferred Stock
Series CF Preferred Stock
Common Stock
Accumulated Deficit
Additional Paid-in Capital
Total
Beginning balance at Dec. 31, 2020 $ 2,071 $ 565 $ 2,075 $ 0   $ 593 $ 904 $ 83 $ 0 $ (33,345,997) $ 27,482,061 $ (5,857,645)
Beginning balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 20,754,717     5,932,742 9,032,330 836,331 266      
Issuance of common stock in public offering                     10,000,002 10,000,002
Issuance of common stock in public offering (in shares)                 964      
Offering costs                     (2,116,957) (2,116,957)
Warrants issued in connection with note                     501,658 501,658
Warrants issued in connection with note (in shares)                 52      
Stock-based compensation                     4,278,337 4,278,337
Stock-based compensation (Shares)                 29      
Net Income (loss)                   (32,357,957)   (32,357,957)
Conversion of preferred stock into common stock $ (2,071) $ (565) $ (2,075)     $ (593) $ (904) $ (83)     6,291 6,291
Conversion of preferred stock into common stock (shares) (20,714,518) (5,654,072) (20,754,717)     (5,932,742) (9,032,330) (836,331) 1,611      
Exercise of over-allotment option, net of offering costs                     1,364,997 1,364,997
Exercise of over-allotment option, net of offering costs (in shares)                 145      
Conversion of debt into common stock (In shares)                 454      
Conversion of related party notes and payables into common stock                     257,515 257,515
Conversion of related party notes and payables into common stock (in shares)                 61      
Common stock issued in connection with business combination                     11,428,738 11,428,738
Common stock issued in connection with business combination (in shares)                 1,318      
Exercise of warrants                     1,768,046 1,768,046
Exercise of warrants (in shares)                 155      
Common stock issued pursuant to consulting agreement                     595,500 595,500
Common stock issued pursuant to consulting agreement (in shares)                 97      
Issuance of common stock pursuant to equity line of credit                     367,696 367,696
Issuance of common stock pursuant to equity line of credit (in shares)                 51      
Ending balance (in shares) at Dec. 31, 2021                 521      
Ending balance at Dec. 31, 2021                 $ 0 (65,703,954) 58,614,173 (7,089,781)
Conversion of notes into common stock                     1,201,582 1,201,582
Conversion of notes into common stock (in shares)                 350      
Stock-based compensation                     139,093 139,093
Net Income (loss)                   (7,832,942)   (7,832,942)
Ending balance (in shares) at Mar. 31, 2022                 870      
Ending balance at Mar. 31, 2022                 $ 0 (73,536,896) 59,954,848 (13,582,048)
Beginning balance at Dec. 31, 2021                 $ 0 (65,703,954) 58,614,173 (7,089,781)
Beginning balance (in shares) at Dec. 31, 2021                 521      
Net Income (loss)                       (17,366,866)
Ending balance (in shares) at Jun. 30, 2022                 16,470      
Ending balance at Jun. 30, 2022                 $ 2 (83,070,820) 68,190,600 (14,880,218)
Beginning balance at Dec. 31, 2021                 $ 0 (65,703,954) 58,614,173 (7,089,781)
Beginning balance (in shares) at Dec. 31, 2021                 521      
Issuance of common stock in public offering                 $ 1   9,347,449 9,347,450
Issuance of common stock in public offering (in shares)                 14,956      
Offering costs                     (2,921,646) (2,921,646)
Conversion of notes and derivative liability into common stock                 $ 8   11,983,381 11,983,389
Conversion of notes and derivative liability into common stock (in shares)                 79,807      
Stock-based compensation                     479,038 479,038
Net Income (loss)                   (38,043,362)   (38,043,362)
Issuance of common stock and exercise of pre-funded warrants in public offering (in shares)                 72,727      
Issuance of common stock and exercise of pre-funded warrants in public offering                 $ 7   9,999,989 9,999,996
Common stock issued in connection with business combination                     1,000,000 1,000,000
Common stock issued in connection with business combination (in shares)                 3,636      
Common stock issued pursuant to consulting agreement                     123,000 123,000
Common stock issued pursuant to consulting agreement (in shares)                 30      
Warrant and common shares issued with notes                     1,368,741 1,368,741
Warrant and common shares issued with notes (in shares)                 2,400      
Conversion of venture debt into Series A convertible preferred stock       $ 1             6,299,999 6,300,000
Conversion of venture debt into Series A convertible preferred stock (in shares)       6,300                
Ending balance (in shares) at Dec. 31, 2022       6,300         178,758      
Ending balance at Dec. 31, 2022       $ 1         $ 18 (103,747,316) 96,294,123 (7,453,174)
Beginning balance at Mar. 31, 2022                 $ 0 (73,536,896) 59,954,848 (13,582,048)
Beginning balance (in shares) at Mar. 31, 2022                 870      
Issuance of common stock in public offering                 $ 1   9,347,449 9,347,450
Issuance of common stock in public offering (in shares)                 14,956      
Offering costs                     (1,930,486) (1,930,486)
Conversion of notes and derivative liability into common stock                     600,790 600,790
Conversion of notes and derivative liability into common stock (in shares)                 644      
Warrants issued in connection with note                     98,241 98,241
Stock-based compensation                     119,759 119,759
Net Income (loss)                   (9,533,924)   (9,533,924)
Ending balance (in shares) at Jun. 30, 2022                 16,470      
Ending balance at Jun. 30, 2022                 $ 2 (83,070,820) 68,190,600 (14,880,218)
Beginning balance at Dec. 31, 2022       $ 1         $ 18 (103,747,316) 96,294,123 (7,453,174)
Beginning balance (in shares) at Dec. 31, 2022       6,300         178,758      
Issuance of common stock pursuant to private placement                 $ 5   4,999,998 5,000,003
Issuance of common stock pursuant to private placement (in shares)                 50,890      
Offering costs                     (536,927) (536,927)
Shares issued for services                     499,338 499,338
Shares issued for services (in shares)                 4,756      
Shares and warrants issued with notes                     658,494 658,494
Shares and warrants issued with notes (in shares)                 4,400      
Stock-based compensation                     105,594 105,594
Net Income (loss)                   (6,136,349)   (6,136,349)
Ending balance (in shares) at Mar. 31, 2023       6,300         238,803      
Ending balance at Mar. 31, 2023       $ 1         $ 23 (109,883,665) 102,020,620 (7,863,022)
Beginning balance at Dec. 31, 2022       $ 1         $ 18 (103,747,316) 96,294,123 $ (7,453,174)
Beginning balance (in shares) at Dec. 31, 2022       6,300         178,758      
Issuance of common stock pursuant to private placement (in shares)                       50,890
Net Income (loss)                       $ (1,092,088)
Ending balance (in shares) at Jun. 30, 2023     1 6,300 5,761       316,906      
Ending balance at Jun. 30, 2023       $ 1 $ 1       $ 31 (104,839,404) 109,263,332 4,423,960
Beginning balance at Mar. 31, 2023       $ 1         $ 23 (109,883,665) 102,020,620 (7,863,022)
Beginning balance (in shares) at Mar. 31, 2023       6,300         238,803      
Conversion of notes into preferred stock         $ 1           5,759,177 5,759,177
Conversion of notes into preferred stock (in shares)         5,761              
Issuance of Series B preferred stock                     25,000 25,000
Issuance of Series B preferred stock (in shares)     1                  
Issuance of common stock pursuant to disposition                 $ 8   1,357,035 1,357,043
Issuance of common stock pursuant to disposition (in shares)                 78,103      
Stock-based compensation                     101,500 101,500
Net Income (loss)                   5,044,260   5,044,260
Ending balance (in shares) at Jun. 30, 2023     1 6,300 5,761       316,906      
Ending balance at Jun. 30, 2023       $ 1 $ 1       $ 31 $ (104,839,404) $ 109,263,332 $ 4,423,960